Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Return on Equity (2016 - 2025)

Historic Return on Equity for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to 0.48%.

  • Altimmune's Return on Equity rose 2400.0% to 0.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.48%, marking a year-over-year increase of 2400.0%. This contributed to the annual value of 0.6% for FY2024, which is 1300.0% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Return on Equity is 0.48%, which was up 2400.0% from 0.58% recorded in Q2 2025.
  • Altimmune's 5-year Return on Equity high stood at 0.25% for Q1 2021, and its period low was 0.74% during Q4 2024.
  • In the last 5 years, Altimmune's Return on Equity had a median value of 0.49% in 2023 and averaged 0.51%.
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 3100bps in 2021, then crashed by -2800bps in 2022.
  • Altimmune's Return on Equity (Quarter) stood at 0.48% in 2021, then increased by 9bps to 0.43% in 2022, then fell by -18bps to 0.51% in 2023, then crashed by -44bps to 0.74% in 2024, then soared by 35bps to 0.48% in 2025.
  • Its Return on Equity was 0.48% in Q3 2025, compared to 0.58% in Q2 2025 and 0.68% in Q1 2025.